These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 31792138)
21. Measuring the Infectious Titer of Recombinant Adenovirus Using Tissue Culture Infection Dose 50% (TCID Lock M; Korn M; Wilson J; Sena-Esteves M; Gao G Cold Spring Harb Protoc; 2019 Aug; 2019(8):. PubMed ID: 31371467 [TBL] [Abstract][Full Text] [Related]
22. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Wildner O; Hoffmann D; Jogler C; Uberla K Cancer Gene Ther; 2003 Oct; 10(10):791-802. PubMed ID: 14502232 [TBL] [Abstract][Full Text] [Related]
23. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Gao GP; Engdahl RK; Wilson JM Hum Gene Ther; 2000 Jan; 11(1):213-9. PubMed ID: 10646652 [TBL] [Abstract][Full Text] [Related]
24. A Method to Generate and Rescue Recombinant Adenovirus Devoid of Replication-Competent Particles in Animal-Origin-Free Culture Medium. Elahi SM; Jiang J; Nazemi-Moghaddam N; Gilbert R Viruses; 2023 Oct; 15(11):. PubMed ID: 38005830 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Kim J; Cho JY; Kim JH; Jung KC; Yun CO Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522 [TBL] [Abstract][Full Text] [Related]
26. Development of a packaging cell line for propagation of replication-deficient adenovirus vector. Kim JS; Lee SH; Cho YS; Park K; Kim YH; Lee JH Exp Mol Med; 2001 Sep; 33(3):145-9. PubMed ID: 11642550 [TBL] [Abstract][Full Text] [Related]
27. Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors. Barry MA; Weaver EA; Hofherr SE Methods Mol Biol; 2010; 651():227-39. PubMed ID: 20686969 [TBL] [Abstract][Full Text] [Related]
28. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655 [TBL] [Abstract][Full Text] [Related]
29. Assessing UV Inactivation of Adenovirus 41 Using Integrated Cell Culture Real-Time qPCR/RT-qPCR. Ding N; Craik SA; Pang X; Lee B; Neumann NF Water Environ Res; 2017 Apr; 89(4):323-329. PubMed ID: 28377001 [TBL] [Abstract][Full Text] [Related]
30. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932 [TBL] [Abstract][Full Text] [Related]
31. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984 [TBL] [Abstract][Full Text] [Related]
32. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Zhu J; Grace M; Casale J; Chang AT; Musco ML; Bordens R; Greenberg R; Schaefer E; Indelicato SR Hum Gene Ther; 1999 Jan; 10(1):113-21. PubMed ID: 10022536 [TBL] [Abstract][Full Text] [Related]
33. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Puntel M; Curtin JF; Zirger JM; Muhammad AK; Xiong W; Liu C; Hu J; Kroeger KM; Czer P; Sciascia S; Mondkar S; Lowenstein PR; Castro MG Hum Gene Ther; 2006 May; 17(5):531-44. PubMed ID: 16716110 [TBL] [Abstract][Full Text] [Related]
34. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. Gorziglia MI; Kadan MJ; Yei S; Lim J; Lee GM; Luthra R; Trapnell BC J Virol; 1996 Jun; 70(6):4173-8. PubMed ID: 8648763 [TBL] [Abstract][Full Text] [Related]
35. An improved infectivity assay combining cell culture with real-time PCR for rapid quantification of human adenoviruses 41 and semi-quantification of human adenovirus in sewage. Rodríguez RA; Polston PM; Wu MJ; Wu J; Sobsey MD Water Res; 2013 Jun; 47(9):3183-91. PubMed ID: 23579085 [TBL] [Abstract][Full Text] [Related]
36. E1A genes of adenovirus type 2 and type 5 are expressed at different levels. Möritz C; Dobbelstein M Arch Virol; 2006 Jun; 151(6):1085-92. PubMed ID: 16421637 [TBL] [Abstract][Full Text] [Related]
37. Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens. Wang F; Patel DK; Antonello JM; Washabaugh MW; Kaslow DC; Shiver JW; Chirmule N Hum Gene Ther; 2003 Jan; 14(1):25-36. PubMed ID: 12573056 [TBL] [Abstract][Full Text] [Related]
38. Construction of a novel oncolytic adenoviral vector and its biological characteristics. Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979 [TBL] [Abstract][Full Text] [Related]
39. Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malignancy. Ghosh S; Duigou GJ Cancer Res; 2005 Oct; 65(19):8936-43. PubMed ID: 16204066 [TBL] [Abstract][Full Text] [Related]